Spero Therapeutics, Inc. (SPRO)
1.13
+0.01
(+0.89%)
USD |
NASDAQ |
Sep 11, 16:00
1.14
+0.01
(+0.88%)
After-Hours: 20:00
Spero Therapeutics Enterprise Value : 16.98M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 16.98M |
| September 10, 2026 | 16.39M |
| September 09, 2026 | 19.30M |
| September 08, 2026 | 20.46M |
| September 04, 2026 | 21.63M |
| September 03, 2026 | 22.21M |
| September 02, 2026 | 22.21M |
| September 01, 2026 | 21.05M |
| August 31, 2026 | 22.21M |
| August 28, 2026 | 21.05M |
| August 27, 2026 | 21.63M |
| August 26, 2026 | 22.21M |
| August 25, 2026 | 22.79M |
| August 24, 2026 | 21.92M |
| August 21, 2026 | 22.21M |
| August 20, 2026 | 21.63M |
| August 19, 2026 | 22.79M |
| August 18, 2026 | 21.05M |
| August 17, 2026 | 20.46M |
| August 14, 2026 | 22.79M |
| August 13, 2026 | 23.37M |
| August 12, 2026 | 20.46M |
| August 11, 2026 | 22.79M |
| August 10, 2026 | 22.79M |
| August 07, 2026 | 24.53M |
| Date | Value |
|---|---|
| August 06, 2026 | 25.12M |
| August 05, 2026 | 24.53M |
| August 04, 2026 | 22.79M |
| August 03, 2026 | 18.14M |
| July 31, 2026 | 19.30M |
| July 30, 2026 | 21.05M |
| July 29, 2026 | 20.46M |
| July 28, 2026 | 20.75M |
| July 27, 2026 | 19.88M |
| July 24, 2026 | 20.46M |
| July 23, 2026 | 18.72M |
| July 22, 2026 | 25.12M |
| July 21, 2026 | 31.51M |
| July 20, 2026 | 35.00M |
| July 17, 2026 | 43.14M |
| July 16, 2026 | 42.56M |
| July 15, 2026 | 50.12M |
| July 14, 2026 | 50.12M |
| July 13, 2026 | 78.03M |
| July 10, 2026 | 73.38M |
| July 09, 2026 | 74.54M |
| July 08, 2026 | 77.45M |
| July 07, 2026 | 76.87M |
| July 06, 2026 | 78.61M |
| July 02, 2026 | 79.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 74.26M |
| Fortress Biotech, Inc. | -17.37M |
| Kura Oncology, Inc. | 518.62M |
| Legend Biotech Corp. | 2.925B |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.552M |
| Total Expenses (Quarterly) | 9.552M |
| EPS Diluted (Quarterly) | -0.1648 |
| Earnings Yield | 9.65% |
| Operating Earnings Yield | 3.95% |
| Normalized Earnings Yield | 10.31 |